Analysts’ Weekly Ratings Updates for Zoetis (ZTS)

Zoetis (NYSE: ZTS) recently received a number of ratings updates from brokerages and research firms:

• 3/2/2026 – Zoetis had its “outperform” rating reaffirmed by William Blair.
• 2/26/2026 – Zoetis had its “buy” rating reaffirmed by BTIG Research. They now have a $160.00 price target on the stock.
• 2/21/2026 – Zoetis was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/13/2026 – Zoetis had its price target raised by Bank of America Corporation from $135.00 to $140.00. They now have a “neutral” rating on the stock.
• 1/29/2026 – Zoetis was given a new $136.00 price target by UBS Group AG.
• 1/28/2026 – Zoetis was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 1/23/2026 – Zoetis was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/22/2026 – Zoetis had its “neutral” rating reaffirmed by Piper Sandler. They now have a $135.00 price target on the stock, down from $190.00.
• 1/22/2026 – Zoetis was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $135.00 price target on the stock, down from $190.00.
• 1/13/2026 – Zoetis was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.